| Year |
Citation |
Score |
| 2019 |
Xu Y, Poggio M, Jin HY, Shi Z, Forester CM, Wang Y, Stumpf CR, Xue L, Devericks E, So L, Nguyen HG, Griselin A, Gordan JD, Umetsu SE, Reich SH, et al. Translation control of the immune checkpoint in cancer and its therapeutic targeting. Nature Medicine. PMID 30643286 DOI: 10.1038/S41591-018-0321-2 |
0.359 |
|
| 2016 |
So L, Lee J, Palafox M, Mallya S, Woxland CG, Arguello M, Truitt ML, Sonenberg N, Ruggero D, Fruman DA. The 4E-BP-eIF4E axis promotes rapamycin-sensitive growth and proliferation in lymphocytes. Science Signaling. 9: ra57. PMID 27245614 DOI: 10.1126/Scisignal.Aad8463 |
0.612 |
|
| 2015 |
Vo T, Lee JS, So L, Beagle B, Janes MR, Fruman DA. Abstract IA16: Mechanisms of resistance to mTOR inhibitors in leukemia and lymphoma Molecular Cancer Therapeutics. 14. DOI: 10.1158/1538-8514.Pi3K14-Ia16 |
0.776 |
|
| 2014 |
Limon JJ, So L, Jellbauer S, Chiu H, Corado J, Sykes SM, Raffatellu M, Fruman DA. mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition. Proceedings of the National Academy of Sciences of the United States of America. 111: E5076-85. PMID 25385646 DOI: 10.1073/Pnas.1407104111 |
0.737 |
|
| 2014 |
Yea SS, So L, Mallya S, Lee J, Rajasekaran K, Malarkannan S, Fruman DA. Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function. Plos One. 9: e99486. PMID 24915189 DOI: 10.1371/Journal.Pone.0099486 |
0.761 |
|
| 2014 |
Mallya S, Fitch BA, Lee JS, So L, Janes MR, Fruman DA. Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1. Plos One. 9: e88865. PMID 24586420 DOI: 10.1371/Journal.Pone.0088865 |
0.76 |
|
| 2013 |
So L, Yea SS, Oak JS, Lu M, Manmadhan A, Ke QH, Janes MR, Kessler LV, Kucharski JM, Li LS, Martin MB, Ren P, Jessen KA, Liu Y, Rommel C, et al. Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function. The Journal of Biological Chemistry. 288: 5718-31. PMID 23275335 DOI: 10.1074/Jbc.M112.379446 |
0.689 |
|
| 2012 |
So L, Fruman DA. PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances. The Biochemical Journal. 442: 465-81. PMID 22364281 DOI: 10.1042/Bj20112092 |
0.707 |
|
| 2010 |
Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST, Konopleva M, Martin MB, Ren P, Liu Y, Rommel C, et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nature Medicine. 16: 205-13. PMID 20072130 DOI: 10.1038/Nm.2091 |
0.767 |
|
| 2010 |
Fruman DA, Janes MR, Limon JJ, So L, Chen J, Martin MB, Ren P, Liu Y, Rommel C. Abstract 1798: TORC1/2 inhibitors have more potent anti-leukemic efficacy and are less immunosuppressive than rapamycin Cancer Research. 70: 1798-1798. DOI: 10.1158/1538-7445.Am10-1798 |
0.782 |
|
| Show low-probability matches. |